Isis Pharmaceuticals' Phase I Cancer Drugs
- Isis Pharmaceuticals says that Phase I clinical trials of two of itsanticancer compounds, ISIS 5332 and ISIS 3521, are nearing completion and seem to show safety and preliminary evidence of response in some patients. Plans are underway to begin Phase II trials for the compounds in second-half 1997 in a range of tumors. The company also plans to begin Phase I trials for a third antitumor compound, ISIS 2503, in mid-year, and hopes to complete Phase II trials of ISIS 2922 (fomivirsen), for the treatment of cytomegalovirus retinitis, later this year.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze